 |
 |
 |
 |
 |
October 2008: VOLUME
1, NUMBER 10
 |
 |
 |
 |
 |
 |
 |
 |
Editor’s
Note:
Refer a Colleague
Share the benefits of this free subscription with your associates by sending them a personal invitation to sign up. |
|
 |
 |
 |
 |
|
 |
 |
 |
 |
Acne Update
In
this Issue...
Acne vulgaris is the most common facial dermatologic disorder encountered in clinical practice. Although the condition affects mainly teenagers, many individuals experience acne onset early in their preteen years or in later adulthood. Despite the common nature of acne vulgaris, effective control of the condition remains a formidable challenge primarily because of the chronicity of the disorder. Management of acne vulgaris involves several important factors, including grading of disease severity, appropriate selection of medications, consideration of potential adverse effects of therapy, development of a convenient treatment regimen, and enhancement of patient compliance.
Most patients with mild to moderate acne vulgaris require treatment with a combination of topical agents and, in some cases, an oral antibiotic. Treatment outcomes are maximized by using a combination approach that is convenient, well tolerated, and includes different mechanisms of action. In this issue, we discuss antibiotic use in patients with acne vulgaris, topical retinoids as part of combination therapy, the incidence of acne flaring following initiation of topical retinoid therapy, and the use of oral contraceptives in female patients with acne vulgaris. |
|
 |
|
  |
 |
 |
|
 |
Program
Directors
Bernard
A. Cohen, MD
Professor of Pediatrics and Dermatology
and Director of Pediatric Dermatology,
Johns Hopkins Children’s Center
Baltimore, MD
Susan
Matra Rabizadeh, MD, MBA
Private Practice
Los Angeles, CA
Mark
Lebwohl, MD
Professor and Chairman
Department of Dermatology
The Mount Sinai School of Medicine
New York, NY
Elizabeth
Sloand, PhD, CRNP
Assistant Professor of Pediatric
Nursing
The Johns Hopkins University
School of Nursing
Baltimore, MD |
|
|
 |
 |
 |
 |
GUEST
AUTHOR OF THE MONTH |
|
 |
 |
 |
 |
 |
Commentary
& Reviews: |
|
James Q. Del Rosso DO, FAOCD
Dermatology Residency Director
Valley Hospital Medical Center
Las Vegas, Nevada |
|
 |
Guest
Faculty Disclosures
Dr. Del Rosso has served as a consultant, speaker and investigator for Allergan, Coria, Galderma, Intendis, Medicis, Ortho Neutrogena, Onset, QLT, Quinnova, Ranbaxy, SkinMedica, Stiefel, Triax, Unilever and Warner Chilcott.
Unlabeled/Unapproved Uses
The author has indicated that
there will be no reference to unlabeled or unapproved uses of drugs
or products in this presentation.
Program
Directors’ Disclosures |
|
|
 |
|
 |
 |
 |
At
the conclusion of this activity, participants should be able to:
 |
 |
Explain the rationale behind combination therapy for the management of acne vulgaris |
 |
 |
 |
Outline clinical considerations regarding Propionibacterium acnes resistance in the treatment of acne vulgaris |
 |
 |
 |
Describe a management plan for individuals with acne vulgaris based on clinical presentation and patient-specific factors |
|
|
 |
|
 |
 |
|
 |
 |
 |
COMPLETE
THE
POST-TEST
Step
1.
Click on the appropriate link below. This
will take you to the post-test.
Step
2.
If you have participated in a Johns Hopkins
on-line course, login. Otherwise, please register.
Step
3.
Complete the post-test and course evaluation.
Step
4.
Print out your certificate.
|
 |
 |
|
 |
|